Patents by Inventor Joel Kralj
Joel Kralj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200191776Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but—for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context.Type: ApplicationFiled: February 24, 2020Publication date: June 18, 2020Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
-
Patent number: 10613079Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease.Type: GrantFiled: September 13, 2018Date of Patent: April 7, 2020Assignee: Q-STATE BIOSCIENCES, INC.Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
-
Patent number: 10352945Abstract: The invention provides methods, cells and constructs for optical measurement of membrane potential. These methods can be used in cells that are not accessible to presently available methods using electrodes. The methods can be directed to, for example, high-throughput drug screening assays to determine agents that can affect membrane potential of a target cell.Type: GrantFiled: October 13, 2017Date of Patent: July 16, 2019Assignee: President and Fellows of Harvard CollegeInventors: Adam Ezra Cohen, Joel Kralj, Adam D. Douglass
-
Publication number: 20190025291Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context.Type: ApplicationFiled: September 13, 2018Publication date: January 24, 2019Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
-
Patent number: 10161937Abstract: The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology.Type: GrantFiled: July 10, 2017Date of Patent: December 25, 2018Assignee: President and Fellows of Harvard CollegeInventors: Adam Ezra Cohen, Joel Kralj, Adam D. Douglass, Daniel Hochbaum
-
Patent number: 10107796Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease.Type: GrantFiled: January 4, 2017Date of Patent: October 23, 2018Assignee: Q-STATE BIOSCIENCES, INC.Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
-
Patent number: 10048275Abstract: Screening compounds by exposing a plurality of cardiomyocytes to a compound, wherein the cardiomyocytes express an optogenetic reporter of membrane potential and an optogenetic reporter of calcium level; receiving light from the optogenetic reporter of membrane potential; creating an AP waveform using the received light; and analyzing the AP waveform to determine the presence or absence of a risk for arrhythmia associated with the compound.Type: GrantFiled: March 11, 2016Date of Patent: August 14, 2018Assignee: Q-STATE BIOSCIENCES, INC.Inventors: Joel Kralj, Graham Dempsey, Christopher Werley, Adam Cohen
-
Publication number: 20180031553Abstract: The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology.Type: ApplicationFiled: July 10, 2017Publication date: February 1, 2018Applicant: President and Fellows of Harvard CollegeInventors: Adam Ezra Cohen, Joel Kralj, Adam D. Douglass, Daniel Hochbaum
-
Publication number: 20180031572Abstract: The invention provides methods, cells and constructs for optical measurement of membrane potential. These methods can be used in cells that are not accessible to presently available methods using electrodes. The methods can be directed to, for example, high-throughput drug screening assays to determine agents that can affect membrane potential of a target cell.Type: ApplicationFiled: October 13, 2017Publication date: February 1, 2018Applicant: President and Fellows of Harvard CollegeInventors: Adam Ezra Cohen, Joel Kralj, Adam D. Douglass
-
Patent number: 9791455Abstract: The invention provides methods, cells and constructs for optical measurement of membrane potential. These methods can be used in cells that are not accessible to presently available methods using electrodes. The methods can be directed to, for example, high-throughput drug screening assays to determine agents that can affect membrane potential of a target cell.Type: GrantFiled: June 15, 2015Date of Patent: October 17, 2017Assignee: President and Fellows of Harvard CollegeInventors: Adam E. Cohen, Joel Kralj, Adam D. Douglass
-
Publication number: 20170292961Abstract: The invention relates to methods of assessing communication between cells. Methods of the invention use optical reporters of cellular electrical activity to evaluate signal propagation between cells and can be used to study an individual synapse or a complex network of interconnected cells. Aspects of the invention provide a method for characterizing signal propagation between cells. The method includes providing a first cell containing a light-generating reporter and a second cell, in which the first cell and the second cell are in communication. The second cell may contain an optical actuator of cellular electrical activity. The second cell is exposed to a stimulus and an optical signal from the first cell is detected.Type: ApplicationFiled: October 2, 2015Publication date: October 12, 2017Inventors: Adam Cohen, Kevin C. Eggan, Joel Kralj, Daniel Hochbaum, Graham Dempsey
-
Patent number: 9702874Abstract: The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology.Type: GrantFiled: November 16, 2015Date of Patent: July 11, 2017Assignee: President and Fellows of Harvard CollegeInventors: Adam E. Cohen, Joel Kralj, Adam D. Douglass, Daniel Hochbaum
-
Publication number: 20170115279Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context.Type: ApplicationFiled: January 4, 2017Publication date: April 27, 2017Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
-
Patent number: 9594075Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context. The optical signature of the cell, or the difference between the signature and the control signature, is correlated to a diagnosis of the neurodegenerative disease.Type: GrantFiled: April 21, 2015Date of Patent: March 14, 2017Assignee: Q-State Biosciences, Inc.Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
-
Publication number: 20160282327Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context.Type: ApplicationFiled: May 10, 2016Publication date: September 29, 2016Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
-
Publication number: 20160266144Abstract: Screening compounds by exposing a plurality of cardiomyocytes to a compound, wherein the cardiomyocytes express an optogenetic reporter of membrane potential and an optogenetic reporter of calcium level; receiving light from the optogenetic reporter of membrane potential; creating an AP waveform using the received light; and analyzing the AP waveform to determine the presence or absence of a risk for arrhythmia associated with the compound.Type: ApplicationFiled: March 11, 2016Publication date: September 15, 2016Inventors: Joel Kralj, Graham Dempsey, Christopher Werley, Adam Cohen
-
Publication number: 20160069876Abstract: The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology.Type: ApplicationFiled: November 16, 2015Publication date: March 10, 2016Applicant: President and Fellows of Harvard CollegeInventors: Adam E. Cohen, Joel Kralj, Adam D. Douglass, Daniel Hochbaum
-
Patent number: 9207237Abstract: The invention provides methods for characterizing cellular physiology by incorporating into an electrically excitable cell an optical reporter of, and an optical actuator of, electrical activity. A signal is obtained from the optical reporter in response to a stimulation of the cell. Either or both of the optical reporter and actuator may be based on genetically-encoded rhodopsins incorporated into the cell. The invention provides all optical methods that may be used instead of, or as a complement to, traditional patch clamp technologies and that can provide rapid, accurate, and flexible assays of cellular physiology.Type: GrantFiled: June 12, 2014Date of Patent: December 8, 2015Assignee: President and Fellows of Harvard CollegeInventors: Adam E. Cohen, Joel Kralj, Adam D. Douglass, Daniel Hochbaum
-
Publication number: 20150301030Abstract: Disease models for Parkinson's disease are disclosed comprising a dopaminergic neuron having one or more phenotypic or genotypic characteristics of Parkinson's disease where the neuron expresses an optical reporter of, and an optical activator of, electrical activity and that exhibits an optical signature in response to neural stimulation. Cells may optionally include an indicator of intracellular calcium levels. Transformed neurons may be optically evaluated for action potentials to track the development of disease, evaluate potential therapies, diagnosis of disease, and to identify mutations and genes associated with disease development and progression.Type: ApplicationFiled: April 21, 2015Publication date: October 22, 2015Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis
-
Publication number: 20150301029Abstract: The invention generally relates to optical methods for the diagnosis of neuronal condition by converting a cell from a patient into a neuron and optically evaluating action potentials of that cell in vitro. The cell is transformed with an optical reporter and exhibits an optical signature in response to neural stimulation. Using genome-editing, a control cell can be made that is isogenic but-for a known mutation and a control signature obtained from the control cell. Thus, methods of the invention reveal potential neurodegenerative effects of a mutation as manifested in a patient's genetic context.Type: ApplicationFiled: April 21, 2015Publication date: October 22, 2015Inventors: Kevin C. Eggan, Adam Cohen, Joel Kralj, Evangelos Kiskinis